1. Signaling Pathways
  2. Cytoskeleton
  3. Integrin

Integrin

Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.

Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.

Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N2584A
    Isoxanthohumol
    Inhibitor 99.91%
    Isoxanthohumol is an orally active flavonoid compound. Isoxanthohumol has biological activities such as anti-tumor, anti-inflammatory, antioxidant, antiviral, antifungal, and inhibition of adipogenesis. Isoxanthohumol can induce apoptosis, autophagy, and migration of tumor cells. Isoxanthohumol is active against viruses such as HSV, BVDV, CMV, and Rhino. Isoxanthohumol can be used for the research of tumors, metabolic, and inflammatory diseases.
    Isoxanthohumol
  • HY-100445
    αvβ1 integrin-IN-1
    Inhibitor 99.51%
    αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects.
    αvβ1 integrin-IN-1
  • HY-13535
    ATN-161
    Antagonist 99.36%
    ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.
    ATN-161
  • HY-145728B
    (R/S)-Alicaforsen
    Inhibitor
    (R/S)-Alicaforsen is the racemate of Alicaforsen composed of R and S configurations. Alicaforsen is a 20-base antisense oligonucleotide inhibiting ICAM-1 production, which is an important adhesion molecule involved in leukocyte migration and trafficking to the site of inflammation.
    (R/S)-Alicaforsen
  • HY-P0278A
    RGD Trifluoroacetate
    99.55%
    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
    RGD Trifluoroacetate
  • HY-14126
    BIO-1211
    Inhibitor 99.81%
    BIO-1211 is a highly selective and orally active α4β1 (VLA-4) inhibitor, with IC50 values of 4 nM and 2 μM for α4β1 and α4β7, respectively.
    BIO-1211
  • HY-19767
    GSK 3008348
    Antagonist 98.04%
    GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer.
    GSK 3008348
  • HY-P9947
    Efalizumab
    98.77%
    Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.
    Efalizumab
  • HY-139702
    α5β1 integrin agonist-1
    Agonist 99.67%
    α5β1 integrin agonist-1 is an α5β1 integrin agonist, with an EC50 of 1.5 nM. α5β1 integrin agonist-1 inhabits α4β1 integrin (IC50 = 2.99 μM) in Jurkat/VCAM-1 adhesion assayα5β1 integrin agonist-1 induces concentration-dependent apoptosis and activates the caspase 3/7 pathway in α5β1 integrin-expressing K562 cancer cells. α5β1 integrin agonist-1 can be used for the study of cancer.
    α5β1 integrin agonist-1
  • HY-P1654
    A20FMDV2
    Inhibitor 98.03%
    A20FMDV2 is a selective αvβ6 integrin inhibitor (IC50: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from foot-and-mouth disease virus and is a 20-amino-acid peptide. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors.
    A20FMDV2
  • HY-W013272
    Hydroxyflutamide
    Inducer 99.77%
    Hydroxyflutamide (HFT) is the active metabolite of Flutamide (HY-B0022) and exhibits oral activity. Hydroxyflutamide is a potent androgen receptor antagonist with an IC50 of 700 nM. Hydroxyflutamide can affect embryonic development and reproductive tract development in mice. Additionally, Hydroxyflutamide can enhance the efficacy of Bacillus Calmette-Guérin (BCG) to better inhibit the progression of bladder cancer. Hydroxyflutamide can be used in research related to tumors and reproductive diseases.
    Hydroxyflutamide
  • HY-P990643
    OS-2966
    Inhibitor 99.62%
    OS-2966 is a humanized antibody expressed in CHO cells, targeting Integrin b1/ITGB1/CD29. OS-2966 carries a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for OS-2966 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    OS-2966
  • HY-120628
    BMS-587101
    Antagonist 99.39%
    BMS-587101 is a potent and orally active antagonist of leukocyte function associated antigen-1 (LFA-1). BMS-587101 has anti-inflammatory effects and can be used for rheumatoid arthritis research.
    BMS-587101
  • HY-101473
    EMD527040
    Inhibitor 99.88%
    EMD527040 is a potent and highly selective αvβ6 antagonist with antifibrotic activities. EMD527040 can be used for carcinoma and liver fibrosis research.
    EMD527040
  • HY-P0178A
    LXW7 TFA
    Inhibitor 98.44%
    LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.
    LXW7 TFA
  • HY-P99473
    Bersanlimab
    Inhibitor ≥99.0%
    Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects.
    Bersanlimab
  • HY-P1187
    HSDVHK-NH2
    Antagonist 99.28%
    HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM).
    HSDVHK-NH2
  • HY-P1868A
    α2β1 Integrin Ligand Peptide TFA
    98.62%
    α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.
    α2β1 Integrin Ligand Peptide TFA
  • HY-153999
    Rondaptivon pegol
    Inhibitor 98.20%
    Rondaptivon pegol (BT200), a pegylated form of the aptamer BT100, inhibits binding of von Willebrand factor (VWF) to platelet glycoprotein GPIb, preventing arterial thrombosis.
    Rondaptivon pegol
  • HY-P1189A
    Echistatin TFA
    Antagonist 98.05%
    Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1.
    Echistatin TFA
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.